Last reviewed · How we verify
NCT04514549
ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME
trial testing Emerald in Rett Syndrome in 21 participants. Completed in 1 March 2023.
1 March 2023
Quick facts
| Lead sponsor | Rett Syndrome Research Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 21 |
| Start date | 23 November 2020 |
| Primary completion | 1 March 2023 |
| Estimated completion | 1 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Emerald
Conditions studied
- Rett Syndrome — all drugs for Rett Syndrome →
Sponsor
Rett Syndrome Research Trust
Who can join
Eligibility, female only, with Rett Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study of the Emerald device in Rett syndrome patients diagnosed with a confirmed MECP2 mutation. MC10 BioStamp nPoint patches will also be assessed with the goal to develop Rett-specific breathing algorithms
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Circulating 4-F<sub>4t</sub>-Neuroprostane and 10-F<sub>4t</sub>-Neuroprostane Are Related to <i>MECP2</i> Gene Mutation and Natural History in Rett Syndrome.
Signorini C, Leoncini S, Durand T, Galano JM, et al · · 2021 · cited 3× · PMID 33921863 · DOI 10.3390/ijms22084240
Verify or expand the search:
- PubMed search for NCT04514549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rett Syndrome
Currently open trials in the same condition.
- NCT06840496 — To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome · Phase 3 · recruiting
- NCT07151950 — Obi Medical Robot: Evaluating Effectiveness Related to Usability · active not recruiting
- NCT06856759 — Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome · EARLY_PHASE1 · recruiting
- NCT07418905 — Technology-supported Motor Rehabilitation for People With Rett Syndrome · NA · active not recruiting
- NCT06152237 — Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) · Phase 1, PHASE2 · active not recruiting
Other Rett Syndrome Research Trust trials
Trials by the same sponsor.
- NCT04900493 — The Rett Syndrome Global Registry · recruiting
- NCT04920110 — Development of the ORCA Communication Measure for Rett Syndrome · completed
- NCT03633058 — A Study to Evaluate Ketamine for the Treatment of Rett Syndrome · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04514549 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rett Syndrome Research Trust
- Last refreshed: 14 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04514549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing